JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study

  • 0Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cancer Medicine +

|

January 13, 2025

|

January 13, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

TERT promoter (TERTp) mutations are key in glioblastoma diagnosis and impact glioma prognosis. This study analyzed TERTp mutation distribution and its correlation with patient outcomes and other molecular alterations in various glioma subtypes.

Area Of Science

  • Neuro-oncology
  • Molecular diagnostics
  • Cancer genomics

Background

  • The 2021 WHO Classification of CNS Tumors emphasizes molecular markers, including TERT promoter (TERTp) mutations, for glioma reclassification.
  • TERTp mutations are critical for diagnosing glioblastoma and understanding glioma heterogeneity.

Purpose Of The Study

  • To investigate the distribution and prognostic significance of TERT promoter mutations in gliomas based on the latest WHO classification.
  • To explore correlations between TERTp mutations and other molecular alterations across different glioma subgroups.

Main Methods

  • Analysis of TERT promoter mutations and 59 other gene alterations/chromosome copy number variations in 207 glioma patients.
  • Patient samples were collected from Peking Union Medical College Hospital between 2011 and 2022.

Main Results

  • TERTp mutations occurred in 4.55% of astrocytomas, 100% of oligodendrogliomas, and 77.92% of glioblastomas.
  • TERTp mutation predicted better prognosis in IDH-mutant grade 2 gliomas but was associated with poorer outcomes in Grade 4 gliomas and IDH-wildtype grade 2/3 gliomas.
  • TERTp mutations showed specific co-occurrence patterns with other molecular markers (e.g., EGFR, CIC, ATRX) in different glioma subtypes.

Conclusions

  • TERTp mutation status is a significant factor influencing glioma prognosis across various subtypes.
  • Understanding TERTp mutation distribution and its molecular correlations can refine prognostic predictions and aid in glioma classification.

Keywords: